Clinical Trials Logo

RSV Infection clinical trials

View clinical trials related to RSV Infection.

Filter by:

NCT ID: NCT06442241 Not yet recruiting - RSV Infection Clinical Trials

A Safety and Immunogenicity Trial of a Respiratory Syncytial Virus Vaccine, LYB005 in Healthy Adults

Start date: July 2024
Phase: Phase 1
Study type: Interventional

A phase 1, randomized, observer-blinded, parallel-controlled, dose escalation study in Australia will evaluate the safety and immunogenicity of the RSV vaccine candidate LYB005 with or without adjuvant in healthy adults aged 18 years and older.

NCT ID: NCT06401720 Enrolling by invitation - Clinical trials for SARS CoV 2 Infection

Age Related Differences in Respiratory Immune Responses in Influenza Virus Infection

NPA-DC
Start date: January 1, 2024
Phase:
Study type: Observational

The goal of this observational study is to understand immune responses to viral airway infection in adults, including the elderly. The main question(s) to answer is/are: Why do some individuals acquire only asymptomatic or mild Influenza A virus (IAV) infection while others become severely ill and even succumb to the same disease? Participants will be asked to donate samples when seeking health care for influenza-like symptoms or if hospitalized for IAV or SARS-CoV-2. Samples asked for are: - Blood sample by venepuncture - Blood sample by capillary sampling - Nasopharyngeal aspirate - Nasopharyngeal swab - Endotracheal tube aspirate - Nasal swab - Nasal curette - Breath Explor (sampling of expired air) Researchers will compare obtained results with the same type of samples from healthy controls.

NCT ID: NCT06318936 Recruiting - RSV Infection Clinical Trials

Respiratory Syncytial Virus (RSV) Burden in Older Adults in Primary Care in The Netherlands

RAPID
Start date: November 1, 2022
Phase:
Study type: Observational

RSV infection is a leading cause of medical care in older adults, sometimes leading to hospital admission and severe outcomes. Although the majority of RSV infections are managed outside hospitals, little is known on the burden of RSV in older adults in the primary care setting. Accurate estimates of the RSV burden in primary care is particularly relevant since vaccines against RSV infection in older adults will likely become available for the general population soon. The use of high-quality point-of-care (POC) molecular viral diagnostics allows to identify RSV infected older adults and would therefore contribute to fill one of the most important gaps in knowledge facilitating implementation of RSV vaccination of older adults With this prospective, observational study, we aim to define the disease burden of RSV infection in older adults in the primary care setting.

NCT ID: NCT06286007 Recruiting - Asthma Clinical Trials

Prevalence and Impact of Pertussis and RSV on Asthma Severity and Control

PRIPASCO
Start date: December 21, 2023
Phase:
Study type: Observational [Patient Registry]

The main objective is to estimate the annual symptomatic incidence of Bordetella pertussis and RSV infections in patients aged 18 years and over with asthma, which will be identified by PCR, for Bordetella pertussis and by PCR for RSV performed at a specific timepoint from onset of symptoms for each symptomatic Acute Respiratory Infection (ARI). A multicentre prospective cohort study will be undertaken in Spain. Thirty-five centres from different autonomous communities in Spain will participate in the study. Participants will be asked to report to the investigator if they experience an asthma exacerbation or symptoms of acute respiratory infection with 2 years follow up

NCT ID: NCT06259487 Recruiting - Heart Failure Clinical Trials

Coordinated Vaccination Against RSV and Influenza in Patients With Chronic Heart Failure and Its Impact on Prognosis.

VACCINE-CHF
Start date: September 15, 2023
Phase: N/A
Study type: Interventional

This prospective, single-centre, open-label, randomized study aims to determine whether coordinated care in administering protective vaccinations (against Respiratory Syncytial Virus (RSV) and influenza) impacts the prognosis of patients with chronic heart failure. The main question it aims to answer is: • Does coordinated care through vaccinations improve the prognosis of patients with chronic heart failure?

NCT ID: NCT06204367 Enrolling by invitation - Bronchiolitis Clinical Trials

Evaluation of Lung Ultrasonography Findings in Newborns With Respiratory Syncytial Virus Bronchiolitis

Start date: December 1, 2023
Phase:
Study type: Observational [Patient Registry]

Respiratory Syncytial Virus (RSV) is a seasonal, highly contagious pathogen belonging to the Pneumoviridae (genus orthopneumovirus), a family of negative-strand RNA viruses. Lung ultrasonography; Today, it has become frequently used in neonatal intensive care units because it is a diagnostic, useful, harmless, radiation-free, bedside, reproducible and practical method. The primary purpose of the study is to record lung ultrasound findings and score and thus to compare the agreement between lung ultrasonography and clinical score in the diagnosis and follow-up of newborn babies who are followed up in the neonatal intensive care unit due to bronchiolitis caused by RSV and other viral factors, which are frequently encountered.

NCT ID: NCT06180993 Recruiting - RSV Infection Clinical Trials

Evaluation of the Effectiveness and Impact of Nirsevimab Administered as Routine Immunization

NIRSE-GAL
Start date: September 25, 2023
Phase:
Study type: Observational

A longitudinal observational study based on routinely collected data on hospital and health care use for RSV infections will be undertaken. The Galician public health registries will be used for data collection including baseline information and follow-up data. Historical data will be retrieved for comparison purposes. The study aims to observe and analyze data from all the eligible children in Galicia for nirsevimab treatment. The number of eligible children is expected to be approximately 14,000 per each RSV season.

NCT ID: NCT06172660 Not yet recruiting - RSV Infection Clinical Trials

Real-World Effectiveness of Perinatal RSV Immunoprophylaxis

Start date: July 1, 2024
Phase:
Study type: Observational

The purpose of this study is to continue evaluating how well the RSV vaccines work as they are currently being used in routine clinical practice. Some of the questions that the investigators hope to answer with this study are: 1) What is the overall effectiveness of these vaccines? 2) How long does immunity last? 3) How effective are the vaccines against new strains? 3) Does the vaccine's effectiveness vary by age?

NCT ID: NCT06170242 Recruiting - RSV Infection Clinical Trials

A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model

Start date: November 20, 2023
Phase: Phase 2
Study type: Interventional

A randomized, Phase 2a, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and antiviral activity of multiple doses of orally administered EDP-323 in healthy subjects infected with RSV-A Memphis 37b. This study is designed to assess the antiviral effect of EDP-323 compared to a placebo control in the respiratory syncytial virus challenge model.

NCT ID: NCT06008457 Completed - Clinical trials for COVID-19 Respiratory Infection

Evaluation of the Labcorp COVID-19+Flu+RSV Test Home Collection Kit

Start date: April 17, 2023
Phase:
Study type: Observational [Patient Registry]

To compare the results obtained by analysis of a self-collected anterior nasal (AN) swab as part of the Labcorp COVID-19+Flu+RSV Test Home Collection Kit to a healthcare provider (HCP)-collected AN swab in patients with symptoms of viral respiratory infection consistent with influenza A (Flu A), influenza B (Flu B), respiratory syncytial virus (RSV) and/or SARS-CoV-2 (C-19).